Multimedia

541 - 560 of 1,448 Results

  • What the Health? From 杨贵妃传媒視頻 Health News

    Will They or Won鈥檛 They (Block the Abortion Pill)?

    Episode 294

    The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as 鈥淒reamers.鈥 Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join 杨贵妃传媒視頻 Health News鈥 Mary Agnes Carey to discuss these issues and more.

    Listen Now
  • An Arm and a Leg

    A $229,000 Medical Bill Goes to Court

    Season 9, Episode 5

    Lisa French was told her surgery would cost $1,337. But the hospital sent her a bill for $229,000, then sued her. The case went all the way to the Colorado Supreme Court. The court鈥檚 ruling could have major implications for determining a 鈥渞easonable price鈥 in health care.

    Listen Now
  • What the Health? From 杨贵妃传媒視頻 Health News

    The Confusing Fate of the Abortion Pill

    Episode 293

    The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA鈥檚 approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join 杨贵妃传媒視頻 Health News chief Washington correspondent Julie Rovner to discuss these issues and more.

    Listen Now
  • What the Health? From 杨贵妃传媒視頻 Health News

    The 鈥楿nwinding’ of Medicaid

    Episode 292

    As of April 1, states were allowed to begin reevaluating Medicaid eligibility for millions of Americans who qualified for the program during the covid-19 pandemic but may no longer meet the income or other requirements. As many as 15 million people could lose health coverage as a result. Meanwhile, the Medicare Hospital Insurance Trust Fund is projected to stay solvent until 2031, its trustees reported, taking some pressure off of lawmakers to finally fix that program鈥檚 underlying financial weaknesses. Alice Miranda Ollstein of Politico, Rachel Roubein of The Washington Post, and Amy Goldstein of The Washington Post join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Daniel Chang, who reported the latest KHN-NPR 鈥淏ill of the Month鈥 feature about a child not yet old enough for kindergarten whose medical bill landed him in collections.

    Listen Now
  • What the Health? From 杨贵妃传媒視頻 Health News

    A Judicial Body Blow to the ACA

    Episode 291

    A federal judge in Texas has dealt a big setback to the Affordable Care Act. The same judge who tried in 2018 to declare the entire ACA unconstitutional has now ruled that the law鈥檚 main provisions for preventive care are unconstitutional and, therefore, unenforceable nationwide. Also this week, North Carolina became the 40th state to expand Medicaid under the ACA. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sandhya Raman of CQ Roll Call join KHN chief Washington correspondent Julie Rovner to discuss these issues and more.

    Listen Now
  • What the Health? From 杨贵妃传媒視頻 Health News

    The Policy, and Politics, of Medicare Advantage

    Episode 290

    Medicare Advantage, the private plan alternative to traditional Medicare, is embroiled in a growing controversy over whether insurers are being overpaid and what it would mean to reduce those payments. Meanwhile, even as maternal mortality in the U.S. continues to rise, providers of care to pregnant women say they鈥檙e leaving states with abortion bans that prevent them from treating pregnancy complications. Margot Sanger-Katz of The New York Times, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN鈥檚 chief Washington correspondent Julie Rovner to discuss these issues and more.

    Listen Now
  • A photo of mifepristone and misoprostol abortion pills.

    Judge Signals He Could Rule to Halt Sales of Common Abortion Pill

    A U.S. District Court case is being widely followed because the judge鈥檚 decision could overturn the FDA鈥檚 approval of mifepristone two decades ago. With abortion rights polling well even in red states, anti-abortion activists are increasingly turning to the courts to achieve their aims.

  • What the Health? From 杨贵妃传媒視頻 Health News

    Judging the Abortion Pill

    Episode 289

    Any day now a conservative federal judge in Texas could upend the national abortion debate by requiring the FDA to rescind its approval of mifepristone, a drug approved in the U.S. more than 20 years ago that is now used in more than half of abortions nationwide. Meanwhile, a controversial study on masks gets a clarification, although it may be too late to change the public impression of what it found. Alice Miranda Ollstein of Politico, Jessie Hellmann of CQ Roll Call, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Plus, for 鈥渆xtra credit,鈥 the panelists suggest health policy stories they read this week they think you should read, too.

    Listen Now